H. Pylori Infection
Conditions
Brief summary
The purpose of this study was to evaluate the efficacy and safety of keverprazan with different doses of amoxicillin for Helicobacter Pylori.
Detailed description
This study is a prospective, single-center, open-label, randomized, parallel-controlled trial. A total of 268 H. pylori positive patients needed to be recruited and were randomized into 2 groups in 1:1 ratio, Group A was the control group and subjects were required to take keverprazan 20mg,bid and amoxicillin 1.0g,tid for 14 days. Group B was the experimental group and subjects were required to take keverprazan 20mg,bid and amoxicillin 1.0g,tid for 14 days. All the above regimens were used for eradication of H. pylori. During the 14-day eradication treatment, all subjects were instructed and asked to record their adverse drug reactions and compliance. On days 7 and 14 of treatment, researchers followed up with patients via WeChat or phone to determine adverse reactions and compliance, and observed and recorded whether subjects experienced any adverse reactions such as nausea, diarrhea, dizziness, bitter taste in the mouth, rash, and constipation. Subjects were seen again 4 weeks after the end of treatment to check for H. pylori eradication by 13C-UBT or 14C-UBT. Patients were encouraged, but not required, to undergo tongue and fecal flora testing before and after H. pylori eradication to determine the short-term effects of different doses of amoxicillin in combination with keverprazan for 14 days on the patient's tongue and intestinal flora.
Interventions
DRUGKeverprazan
Potassium-competitive acid blocker
DRUGAmoxicillin
Antibiotic for H. pylori eradication
Sponsors
Nanjing First Hospital, Nanjing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed with Helicobacter pylori positivity through 13C-UBT or 14C-UBT 2. Patients who have not received eradication treatment for Helicobacter pylori in the past, or who have failed eradication in the early stage but have not received eradication treatment within six months 3. Voluntarily participate in this experiment and sign an informed consent form
Exclusion criteria
1. Allergies to research drugs (such as those allergic to penicillin, amoxicillin, keverprazan) 2. Patients with peptic ulcer 3. Patients who have received Helicobacter pylori eradication treatment within six months 4. Use antibiotics or bismuth medication 4 weeks before starting the study；use P-CAB or PPI 2 weeks before starting the study 5. Using corticosteroids, non steroidal anti-inflammatory drugs, or anticoagulants 6. Those who are using atazanavir, nelfinavir, rilpivirine, itraconazole, tyrosine kinase inhibitors (imatinib, gefitinib, etc.), digoxin, and methyl digoxin 7. History of esophageal or gastric surgery 8. Pregnant or lactating women 9. Suffering from serious concomitant diseases such as liver disease, cardiovascular disease, lung disease, or kidney disease 10. Excessive drinking 11. Gastric mucosa-associated lymphoid tissue lymphoma (MALT), malignant neoplastic diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Helicobacter pylori eradication rate | at least four weeks after completion of the medication | Subjects were seen again 4 weeks after the end of treatment to check for H. pylori eradication by 13C-UBT or 14C-UBT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse even | Within 7 days after completion of therapy | Adverse drug reactions are classified into six types: dose-related, non-dose-related, dose-related and time-related, time-related, withdrawal, and failure of therapy. |
| Compliance Rate | Within 7 days after completion of therapy | Compliance was defined as poor when they had taken less than 80% of the total medication |
Contacts
Primary ContactZhenyu Zhang
Outcome results
None listed